Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup

Ear­li­er Tues­day, End­points News re­port­ed that for­mer Stan­ford pres­i­dent Marc Tessier-Lav­i­gne will lead one of biotech’s biggest-ever start­up launch­es: Xaira Ther­a­peu­tics, which has se­cured over $1 bil­lion to trans­form drug dis­cov­ery and de­vel­op­ment with AI.

The move is sure to raise eye­brows. Tessier-Lav­i­gne re­signed from his post at Stan­ford last sum­mer af­ter an in­tense in­ves­ti­ga­tion found ev­i­dence of fal­si­fied da­ta in some of his old re­search pa­pers. Al­though Tessier-Lav­i­gne was cleared of wrong­do­ing him­self, the pan­el cri­tiqued his lab over­sight and said he was too slow to cor­rect or re­tract the bad da­ta.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.